Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control by Craig, Sarah et al.
BBA - General Subjects 1865 (2021) 129917
Available online 5 May 2021
0304-4165/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Comparison of independent and combined effects of the neurotensin 
receptor agonist, JMV-449, and incretin mimetics on pancreatic islet 
function, glucose homeostasis and appetite control 
S.L. Craig a, V.A. Gault a, C.E. Shiels a, G. Hamscher b, N. Irwin a,* 
a Diabetes Research Group, Ulster University, Coleraine, Northern Ireland, UK 
b Institute of Food Chemistry and Food Biotechnology, Justus Liebig University, Giessen, Germany   







A B S T R A C T   
Background: Neurotensin receptor activation augments the biosctivity of glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP). JMV-449, a C-terminal neurotensin-like fragment with a 
reduced peptide bond, represents a neurotensin receptor agonist. 
Methods: The present study assessed the actions of JMV-449 on pancreatic beta-cells alone, and in combination 
with GIP and GLP-1. Further studies examined the impact of JMV-449 and incretin mimetics on glucose ho-
meostasis and appetite control in mice. 
Results: JMV-449 was resistant to plasma enzyme degradation and induced noticeable dose-dependent insulin- 
releasing actions in BRIN-BD11 beta-cells. In combination with either GIP or GLP-1, JMV-449 augmented (P <
0.05) the insulinotropic actions of both hormones, as well as enhancing (P < 0.001) insulin secretory activity of 
both incretin peptides. JMV-449 also increased beta-cell proliferation and induced significant benefits on beta- 
cell survival in response to cytokine-induced apoptosis. JMV-449 (25 nmol/kg) inhibited (P < 0.05–P < 0.001) 
food intake in overnight fasted lean mice, and enhanced (P < 0.01) the appetite supressing effects of an enzy-
matically stable GLP-1 mimetic. When injected co-jointly with glucose, JMV-449 evoked glucose lowering ac-
tions, but more interestingly significantly augmented (P < 0.05) the glucose lowering effects of established long- 
acting GIP and GLP-1 receptor mimetics. In terms of glucose-induced insulin secretion, only GIP receptor sig-
nalling was associated with increases in insulin concentrations, and this was not enhanced by JMV-449. 
Conclusion: JMV-449 is a neurotensin receptor agonist that positively augments key aspects of the biological 
action profile of GIP and GLP-1. 
General significance: These observations emphasise the, yet untapped, therapeutic potential of combined neu-
rotensin and incretin receptor signalling for diabetes.   
1. Introduction 
Neurotensin was originally considered as an anorexigenic neuro-
peptide [1], with recent studies showing that this peptide is co- 
expressed in enteroendocrine L-cells alongside glucagon-like peptide-1 
(GLP-1) and Peptide YY (PYY), and secreted into the bloodstream 
following nutrient ingestion [2]. Furthermore, neurotensin regulates 
metabolism in a similar manner to GLP-1 and PYY, with additional 
important interactions between all three hormones in terms of blood 
glucose and appetite regulation [2]. Recently, a stable neurotensin 
analogue has been shown to synergise with the clinically approved GLP- 
1 mimetic, liraglutide, to combat obesity and metabolic dysregulation in 
high fat fed mice [3]. In harmony with these observations, the insuli-
notropic bioactivity of the sister incretin hormone of GLP-1, glucose- 
dependent insulinotropic polypeptide (GIP), is enhanced by a peptide 
hormone called xenin [4–6]. Xenin is a peptide co-expressed and 
released with GIP from enteroendocrine K-cells following nutrient 
ingestion [7], with a suggestion that it acts as a neurotensin receptor 
agonist [8]. Interestingly, xenin and neurotensin share significant amino 
acid sequence homology [7,9], with the C-terminal hexapeptide 
sequence of both peptides, namely neurotensin (8–13) and xenin 
(20–25), known to function as biologically active fragment peptides 
[6,10]. 
Taken together, it appears that the biological activity of both incretin 
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hormones could be enhanced through concurrent administration of 
neurotensin related peptides, which would have particular importance 
in the diabetes clinic. Indeed, the intracellular signalling pathways 
stimulated by GIP and GLP-1 receptor activation within pancreatic beta- 
cells are very similar, in that both are initially mediated by activation of 
a specific G-protein coupled receptor with subsequent increases of 
intracellular cAMP [11]. This results in comparable benefits on beta-cell 
function, growth and survival, but some variations in downstream sig-
nalling may account for small efficacy differences between the two 
peptides [11]. Unfortunately, a significant hindrance to the therapeutic 
applicability of neurotensin peptides relates to a short biological half-life 
[12]. However, metabolic stability of neurotensin can be improved 
through appropriate structural modification [10]. As such, introduction 
of a reduced peptide bond, CH2NH, between Lys8 and Lys9 in neuro-
tensin(8–13)-like peptide, generates an enzymatically stable and bio-
logically active peptide that acts as a powerful neurotensin receptor 
agonist [10]. Similarly, enhanced stability and bioactivity of the C-ter-
minal hexapeptide of xenin has also been demonstrated through intro-
duction of a reduced pseudopeptide bond between the two N-terminal 
amino acid residues, to yield Ψ-xenin-6 [13]. More interestingly, Craig 
and colleagues have recently confirmed that Ψ-xenin-6 significantly 
augments the bioactivity of GIP [6]. Furthermore, when Ψ-xenin-6 was 
administered to high fat fed mice in combination with the dipeptidyl 
peptidase-4 (DPP-4) inhibitor drug sitagliptin, clear additive antidia-
betic effects were noted [14]. Together, these observations confirm the 
applicability of metabolically stable C-terminal hexapeptides of either 
neurotensin or xenin. Since the receptor activation profile of xenin and 
related fragment peptides is not yet fully elucidated [7], neurotensin- 
based peptides may offer a more therapeutically attractive option to 
augment the biological action of incretin hormones and improve their 
antidiabetic efficacy. 
In this regard, JMV-449 is a recognised biologically active neuro-
tensin fragment peptide, with a reduced pseudopeptide CH2NH bond 
between Lys8 and Lys9 [10]. In the current study, we initially aimed to 
characterise the effects of JMV-449 at the level of the pancreatic beta- 
cell. Further studies examined the ability of JMV-449 to positively 
interact with GIP and GLP-1 in terms of both in vitro pancreatic beta-cell 
induced insulin secretion, as well as glucose homeostasis, insulin 
secretion and appetite control in mice. 
2. Materials and methods 
2.1. Peptide synthesis 
JMV-449 was obtained from Bio-Techne Ltd. at 99.4% purity 
(Abingdon, United Kingdom). Native GIP and GLP-1 as well as (D-Ala2) 
GIP and exendin-4 were purchased from Synpeptide (Shanghai, China) 
at >95% purity. Before experimentation, all peptides were characterised 
in-house using reverse-phase HPLC and MALDI-TOF MS, as previously 
described [15]. 
2.2. In vitro insulin secretion 
In vitro insulin releasing activity of test peptides was assessed in ro-
dent BRIN-BD11 beta-cells, cultured and maintained as previously 
described [16]. For insulin secretory studies, BRIN-BD11 cells were 
seeded into 24-well plates (150,000 cells per well) and allowed to attach 
overnight at 37 ◦C. Prior to tests, cells were pre-incubated in 
Krebs–Ringer bicarbonate buffer (KRBB) (pH 7.4) supplemented with 
0.5% (w/v) BSA and 1.1 mM glucose (40 min; 37 ◦C). Cells were incu-
bated (20 min) with JMV-449 alone (10− 12–10− 6 M), or in combination 
with GIP (10− 12–10− 6 M) or GLP-1 (10− 12–10− 6 M), as well as combi-
nation of all three test peptides. All samples were stored at − 20 ◦C prior 
to assessment of insulin concentrations by an in-house RIA [17]. 
2.3. In vitro beta-cell proliferation and apoptosis 
BRIN-BD11 beta-cells were used to investigate effects of JMV-449 
(10− 8 and 10− 6 M) on beta-cell proliferation and protection against 
cytokine-induced apoptosis. GLP-1 was employed as a positive control 
for all studies. Ki-67 immunostaining was used to assess effects on 
proliferation. Briefly, cells were seeded onto coverslips (40,000 cells per 
coverslip) and cultured overnight (18 h;37 ◦C), in the presence of test 
peptides (10− 8 and 10− 6 M). Cells were then washed with PBS, and fixed 
using 4% paraformaldehyde. Following antigen retrieval with citrate 
buffer (90 ◦C for 20 min), tissues were blocked using 1.1% BSA for 30 
min. Cells were then incubated with Ki-67 primary antibody (1:500; 
Abcam, ab15580), followed by Alexa Fluor® 488 secondary antibody 
(1:400, Invitrogen, A-11008). Coverslips were washed with PBS, 
mounted on slides for viewing using a fluorescent microscope (Olympus 
System Microscope) and photographed by DP70 camera adapter system. 
Proliferation frequency was expressed as percentage of total cells ana-
lysed. For analysis of the ability of JMV-449 to protect against cytokine- 
induced apoptosis, cells were seeded as above. However, cells were also 
exposed to a cytokine-cocktail (IL-1β 100 U/mL, IFN-γ 20 U/mL, TNF-α 
200 U/mL, all purchased from Sigma-Aldrich) in the presence or absence 
of test peptides (10− 8 and 10− 6 M) for 18 h, with hydrogen peroxide as 
an additional control. TUNEL staining (Roche Diagnostics Ltd., UK) was 
employed to quantify beta-cell apoptosis, as previously described [18]. 
Apoptosis was expressed as percentage of total cells analysed. Approx-
imately 150 cells were analysed per group. 
2.4. Animals 
Animal studies were carried out using male C57BL/6 mice (10 month 
old, Envigo Ltd., UK), all housed individually in an air-conditioned room 
at 22 ± 2 ◦C with a 12 h light: 12 h dark cycle. Animals were maintained 
on standard rodent chow diet (10% fat, 30% protein and 60% carbo-
hydrate, Trouw Nutrition, UK) with ad libitum access to diet and water. 
All animal experiments were carried out in accordance with the UK 
Animal Scientific Procedures Act 1986 and approved by Ulster Univer-
sity Animal Welfare and Ethical Review Body (AWERB). 
2.5. Acute effects on food intake, glucose tolerance and insulin secretion 
in mice 
For in vivo studies, JMV-449 as well as fully characterised enzy-
matically stable forms of GIP and GLP-1 were employed, namely (D-Ala2) 
GIP and exendin-4 [19,20]. For assessment of appetite control, cumu-
lative food intake was assessed in overnight fasted (18 h) mice following 
i.p. injection of saline vehicle (0.9% w/v NaCl) or test peptide(s) (at 
either 2.5 or 25 nmol/kg bw, as appropriate), with food intake measured 
at 30 min intervals for 180 min. For assessment of glucose tolerance, 
blood glucose and plasma insulin concentrations were determined 
immediately prior to and 15, 30, 60 and 105 min after i.p. injection of 
glucose alone (18 mmol/kg bw) or in combination with test peptide(s) 
(each at 25 nmol/kg bw) in 18 h fasted mice. 
2.6. Biochemical analysis 
Blood samples were collected from the cut tip on the tail vein of 
conscious mice into chilled fluoride/heparin glucose micro-centrifuge 
tubes (Sarstedt, Numbrecht, Germany). Blood glucose was measured 
directly using a Contour blood glucose meter. For plasma insulin anal-
ysis, blood samples were collected into chilled fluoride/heparin glucose 
micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) and immedi-
ately centrifuged using a Beckman microcentrifuge (Beckman In-
struments, Galway, Ireland) for 1 min at 13,000g and stored at − 20 ◦C 
prior to insulin RIA [17]. 
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2.7. Statistical analysis 
Statistical analysis was completed using GraphPad PRISM (Version 
5). Results are expressed as means ± SEM and data compared using 
repeated measures ANOVA followed by Student-Newman-Keuls post-hoc 
test. Unpaired Student t-test was used where appropriate. Incremental 
plasma insulin and glucose area under the curve (AUC) were calculated 
using the trapezoidal rule with appropriate baseline subtraction. Groups 
of data were considered significant if P < 0.05. 
3. Results 
3.1. Peptide characterisation and plasma enzyme stability 
MS analysis confirmed identity of JMV-449 (H-LYS-ψ-LYS-PRO-TYR- 
ILE-LEU-OH), with theoretical and experimental masses differing by less 
than 0.5 Da (Table 1). The HPLC profile for JMV-449 confirmed 99.4% 
purity as stated by the manufacturer (data not shown). When incubated 
with murine plasma, JMV-449 remained 100% intact up to 8 h (Table 1). 
3.2. In vitro insulin secretory actions 
In BRIN-BD11 cells, JMV-449 displayed significant (P < 0.05 to P <
0.01) dose-dependent insulin secretory activity at 5.6 mM glucose when 
compared to control cultures (Fig. 1A). At 16.7 mM glucose, significant 
(P < 0.01) insulin secretory actions were displayed only at concentra-
tions of 10− 6 M (Fig. 1B). Importantly, as previously observed, there was 
a clear glucose-dependent increase of insulin secretion in our BRIN BD11 
cell line, with an insulin output of 0.3 ± 0.1 and 0.8 ± 0.1 ng/mL at 5.6 
and 16.7 mM glucose, respectively. When JMV-449 was incubated in 
combination with GIP, significant (P < 0.01 to P < 0.001) dose- 
dependent insulinotropic actions were exhibited at 10− 10 M and 
above, with combination treatment being significantly (P < 0.05) more 
effective than GIP alone at 10− 6 M (Fig. 1C). A similar insulin secretory 
profile for JMV-449 and GIP was evident at 16.7 mM glucose, although 
JMV-449 was unable to augment GIP-induced insulin secretion under 
hyperglycaemic conditions (Fig. 1D). Largely similar insulinotropic 
benefits were observed when JMV-449 was co-incubated with GLP-1 at 
5.6 and 16.7 mM glucose (Fig. 1E,F). However, JMV-449 was able to 
significantly (P < 0.05) augment the insulinotropic actions of 10− 6 M 
GLP-1 at 5.6 mM glucose (Fig. 1E). Interestingly, when JMV-449 was co- 
incubated with both GIP and GLP-1, there was a significant (P < 0.001) 
augmentation of insulin secretion at 5.6 and 16.7 mM glucose (Fig. 1G, 
H). Moreover, combined JMV-449, GIP and GLP-1 treatment at 5.6 mM 
glucose was significantly (P < 0.001) more effective than either GIP or 
GLP-1 alone (Fig. 1G). 
3.3. Beta-cell proliferation and protection against apoptosis 
Similar to GLP-1, JMV-449 significantly (P < 0.001) augmented 
BRIN-BD11 beta-cell proliferation at concentrations of 10− 8 and 10− 6 M 
(Fig. 2A). In relation to protection against cytokine-induced apoptosis, 
JMV-449 significantly (P < 0.05 and P < 0.001) augmented BRIN-BD11 
beta-cell survival in response to cytokine-induced apoptosis at 10− 8 and 
10− 6 M (Fig. 2B), similar to the protective nature of GLP-1. Indeed, at 
concentrations of 10− 6 M, both peptides fully reversed the detrimental 
effect of cytokine culture on beta-cell apoptosis (Fig. 2B) Representative 
images of Ki-67 and TUNEL staining for each incubation are shown in 
Fig. 2C&D. 
3.4. Acute in vivo effects on food intake 
JMV-449, (D-Ala2)GIP, and exendin-4, induced a significant (P <
0.05 and P < 0.01) decrease in food intake in overnight fasted lean mice 
(Fig. 3A,B). JMV-449 was unable to augment the appetite suppressive 
actions of (D-Ala2)GIP or exendin-4 at a dose 25 nmol/kg (Fig. 3A,B). At 
the same peptide dose, combined injection of (D-Ala2)GIP and exendin-4 
had a profound effect to reduce food intake, but this effect was not 
altered by co-injection with JMV-449 (Fig. 3C). However, when 
exendin-4 was administered at a reduced dose of 2.5 nmol/kg, JMV-446 
was able to augment (P < 0.01) the appetite suppressive actions of this 
peptide (Fig. 3D). Following combined administration of 25 nmol/kg (D- 
Ala2)GIP and JMV-449, together with 2.5 nmol/kg exendin-4, there was 
a significant reduction (P < 0.01) of food intake at 15 min post-injection 
when compared to (D-Ala2)GIP plus exendin-4 injection alone (Fig. 3E). 
3.5. Acute in vivo effects on glucose tolerance and insulin secretion 
Administration JMV-449 in combination with glucose to lean mice 
resulted in significantly (P < 0.05 to P < 0.01) decreased individual 
plasma glucose levels at 15 and 30 min post-injection when compared to 
glucose alone control, but this did not translate to significant reductions 
in 0–105 min AUC values (Table 2). However, plasma insulin AUC was 
significantly (P < 0.05) increased by JMV-449, despite lack of effect on 
individual glucose-stimulated insulin concentrations (Table 3). As ex-
pected, (D-Ala2)GIP evoked significant glucose homeostatic and insulin 
secretory actions in mice (Tables 2 & 3). Notably, the overall glucose- 
lowering effect of (D-Ala2)GIP was significantly (P < 0.05) enhanced 
by JMV-449 (Table 2). An essentially similar biological action profile 
was noted when JMV-449 was co-administered with exendin-4, with 
slightly less prominent effects on glucose-induced insulin secretion 
(Tables 2 & 3). As such, both compounds had impressive glucose- 
lowering actions (Table 2), with JMV-449 significantly enhancing the 
glucose homeostatic action of exendin-4 (Table 2). Interestingly, whilst 
combined administration of (D-Ala2)GIP and exendin-4 exerted pro-
nounced effects to reduce blood glucose levels (Table 2), this was not 
associated with obvious benefits on insulin secretion (Table 3). JMV-449 
was unable to enhance the marked positive effects of combined (D-Ala2) 
GIP and exendin-4 injection (Tables 2 & 3). 
4. Discussion 
In the present study, we aimed to characterise the insulinotropic and 
metabolic actions of the neurotensin receptor agonist, JMV-449 [10], as 
well as examining positive interactions between JMV-449 and incretin 
hormones. As such, there is suggestions that the antidiabetic efficacy of 
Table 1 
Amino acid sequence, MALDI-TOF MS analysis and enzymatic stability of JMV-449.  
Peptide Sequence Theoretical molecular mass 
(Da) 
Experimental molecular mass 
(Da) 
Percentage intact peptide 
remaining (%) 
2 h 4 h 6 h 8 h 
JMV-449 H-LYS-ψ-LYS-PRO-TYR-ILE-LEU-OH 747.0 747.2 100 100 100 100 
Neurotensin GLU-LEU-TYR-GLU-ASN-LYS-PRO-ARG-ARG-PRO-TYR-ILE- 
LEU-OH 
1672.9 ND ND ND ND ND 
Molecular mass of JMV-449 was determined using MALDI-TOF MS. Peptide stability was assessed following 0, 2, 4, 6 and 8 h incubation in murine plasma. Degradation 
products were separated using HPLC, analysed by MS, and percentage degradation calculated from peak areas. The amino acid sequence of neurotensin is included for 
comparative purposes. ND, not determined. 
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Fig. 1. Acute effects of JMV-449 alone, and in combination with GIP or GLP-1, on insulin release from BRIN-BD11 cells. 
BRIN-BD11 cells were incubated (20 min) with a range of concentrations (10− 12 to 10− 6 M) of JMV-449 alone (A,B) or in combination with GIP (C,D), GLP-1 (E,F) or 
together with both incretin peptides (G,H) in the presence of (A,C,E,G) 5.6 or (B,D,F,H) 16.7 mM glucose. Insulin release was measured using radioimmunoassay. 
Values represent means ± SEM (n = 8 for insulin). *P < 0.05, **P < 0.01 and ***P < 0.001 compared to respective glucose controls. ∆P < 0.05, ∆∆P < 0.01 and ∆∆∆P 
< 0.001 compared to respective JMV-449 alone. ΩP < 0.05 and ΩΩΩ P < 0.001 compared to 10− 6 M GIP. ΦP < 0.05, ΦΦP < 0.01 and ΦΦΦP < 0.001 compared to 10− 6 
M GLP-1. 
Fig. 2. Effect of JMV-449 on beta-cell proliferation and protection against apoptosis. 
BRIN-BD11 cells were incubated overnight (18 h) with GLP-1 or JMV-449 (each at 10− 8 and 10− 6 M). (A) Proliferation was measured using Ki-67 immunocyto-
chemistry. (B) TUNEL positive apoptotic cells were assessed following 2 h exposure to a cytokine cocktail (IL-1β 100 U/mL, IFN-γ 20 U/mL, TNF-α 200 U/mL) with or 
without co-culture in the presence of GLP-1 or JMV-449 (each at 10− 8 and 10− 6 M). (C,D) Representative images showing the effects of JMV-449 on proliferation (C, 
green) and apoptosis (D, red) at 10− 6 and 10− 8 M in BRIN-BD11 cells. All images shown are X10 magnification. Arrows indicate proliferating (C) or apoptotic (D) 
cells. Values represent means ± SEM (n = 4). (A) ***P < 0.001 compared to respective media control. (B) ***P < 0.001 compared to respective media control. ∆P <
0.05 and ∆∆∆P < 0.001 compared to cytokine cocktail. 
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GIP and GLP-1 can be improved by concurrent activation of neurotensin 
receptors [3,21]. Given that the highly prominent benefits of upregu-
lated incretin receptor activation in various rodent models of obesity- 
Fig. 3. Effects of JMV-449 alone, and in combination with (D-Ala2)GIP or exendin-4, on cumulative food intake in mice. 
(A-C) Cumulative food intake was measured prior to (t = 0) and 30, 60, 90, 120, 150, 180 min after i.p. injection of saline vehicle (0.9% w/v NaCl), JMV-449, (D-Ala2) 
GIP or exendin-4 alone, and in combination (each at 25 nmol/kg bw), in 18 h fasted mice. (D,E) Experiments were repeated in an identical manner, but with exendin- 
4 administered at a dose of 2.5 nmol/kg bw. Values represent means ± SEM (n = 8). *P < 0.05, **P < 0.01 and ***P < 0.001 compared to respective saline 
control.∆∆P < 0.01 compared to exendin-4 (2.5 nmol/kg). ΩΩP < 0.01 compared to JMV-449 (25 nmol/kg). ψψP < 0.01 compared to (D-Ala2)GIP (25 nmol/kg) plus 
exendin-4 (2.5 nmol/kg). 
Table 2 
Effects of JMV-449 alone, and in combination with (D-Ala2)GIP or exendin-4, on 
blood glucose concentrations in mice.  
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Blood glucose concentrations were measured immediately before and 15, 30, 60 
and 105 min after i.p. injection of glucose alone (18 mmol/kg bw) and test 
peptides (each at 25 nmol/kg bw) in 18 h fasted mice. Glucose AUC values for 
0–105 min post injection are also presented. Values represent mean ± SEM for 6 
mice. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to glucose alone. ∆P <
0.05 and ∆∆P < 0.01 compared to JMV-449 alone. ΩP < 0.05 compared to (D- 
Ala2)GIP. πP < 0.05 compared to exendin-4. 
Table 3 
Effects of JMV-449 alone, and in combination with (D-Ala2)GIP or exendin-4, on 
plasma insulin concentrations in mice.  
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Plasma insulin concentrations were measured immediately before and 15, 30, 60 
and 105 min after i.p. injection of glucose alone (18 mmol/kg bw) and test 
peptides (each at 25 nmol/kg bw) in 18 h fasted mice. Plasma insulin AUC values 
for 0–105 min post injection are also presented. Values represent mean ± SEM 
for 6 mice. *P < 0.05 and **P < 0.01 compared to glucose alone. 
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related diabetes have not been fully translated to the clinic, this is of 
significant therapeutic interest. In that regard, bariatric surgery appears 
to be the only intervention that leads to sustained weight loss and po-
tential remission of type 2 diabetes in humans [22], although recent 
observations using once-weekly subcutaneous injection of the GLP-1 
mimetic semaglutide in obese men does offer some encouragement 
[23]. Interestingly, the most effective forms of bariatric surgery are 
associated with dramatic changes in the secretion and action of various 
gut-derived hormones, which is believed to play a major role in pro-
motion of almost immediate resolution of diabetes post-surgery [24]. 
Several studies demonstrate increased circulating neurotensin concen-
trations following bariatric surgery in both rodents and humans 
[3,12,25,26], with surgical-induced modulation of GIP and GLP-1 levels 
already well accepted [24]. Thus, interplay between incretin and neu-
rotensin receptor signalling likely has an appreciable contribution to the 
overall observed benefits of bariatric surgery. However, it should also be 
acknowledged that very low calorie diets do not alter circulating 
incretin hormone levels but can result in a relatively rapid remission of 
type 2 diabetes [27], although prolonged adherence to such strict diets 
appears to be particularly challenging [28]. 
As expected, JMV-449 was completely resistant to plasma enzymatic 
degradation, likely as a consequence of the reduced peptide bond pre-
sent between Lys8 and Lys9 [10]. In keeping with the biological actions 
and insulin secretory profile of neurotensin receptor activation [29], 
JMV-449 evoked clear dose-dependent increases of insulin secretion 
from rodent BRIN-BD11 cells at basal glucose concentrations, which 
were less evident under hyperglycaemic conditions. Thus, this slight 
variability of insulin secretory profile is in complete harmony with 
established bioactivity of neurotensin-like peptides on pancreatic beta- 
cell function [29]. Risk of hypoglycaemia with JMV-449 would be un-
likely given that activation of neurotensin receptors is known to induce 
glucagon secretion at low glucose concentrations [30], but this would 
need to be confirmed for JMV-449. Moreover, JMV-449 imparted in-
dependent benefits on beta-cell growth and survival [31], with potential 
translational benefits in terms of restoration of beta-cell mass and 
function in diabetes that require further study. These positive effects on 
pancreatic beta-cells are very reminiscent of the actions of both incretin 
hormones, GIP and GLP-1 [32]. Indeed, similar to observations with GIP 
and GLP-1 [33], neurotensin, and the related hormone xenin that likely 
functions in part as a neurotensin receptor agonist [8], are evidenced 
locally within the pancreas and believed to impart important autocrine 
or paracrine effects on islet function [31]. As such, we observed clear 
potentiating actions of JMV-449 on GIP- and GLP-1-induced insulin 
secretion at basal glucose concentrations, with similar effects previously 
reported following combined treatment of GIP with xenin [4–7,34–36]. 
Indeed, these positive GIP/xenin interactions ultimately led to devel-
opment of a unimolecular dual-acting GIP/xenin hybrid peptide [37], 
which displays significant and sustained antidiabetic effects in rodent 
models of diabetes [38]. However, it should be noted that the incretin 
hormone potentiating actions of JMV-449 were much less obvious at 
elevated 16.7 mM glucose concentrations in the current setting. 
In full harmony with in vitro findings, JMV-449 possessed prominent 
glucose homeostatic actions in lean healthy mice that were directly 
linked to elevated plasma insulin concentrations. Importantly, positive 
additive benefits were noted in terms of glycaemic status when JMV-449 
was administered together with stable GIP or GLP-1 mimetics, although 
this was not associated with augmentation of glucose-induced insulin 
secretion. This is interesting, and could relate to reduced insulinotropic 
effectiveness of neurotensin at elevated glucose levels [29]. However, 
additive benefits of neurotensin and incretin hormones to improve 
glucose disposal could point towards insulin-independent glucose- 
lowering actions. In this respect, GIP, GLP-1 and neurotensin all exert 
established, but somewhat distinctive, effects on glucagon secretion 
[12,39,40], which could be a factor here. In addition, upregulated 
incretin hormone signalling exerts well described extrapancreatic 
glucose-lowering actions [39,41], which may be augmented by 
neurotensin signalling. Both avenues are complex and as such require 
additional detailed study that is outside the scope of the current inves-
tigation. For example, recent studies with GIP and xenin suggest that 
neurotensin receptor activation can partially reverse the glucose- 
dependent glucagonotropic action of GIP [6], whereas the impact of 
neurotensin on the glucagonostatic action of GLP-1 is unknown. 
Neurotensin receptor activation exerts well documented effects to 
suppress appetite [42], with similar actions noted with GLP-1 [43] and 
more recently GIP [44]. These combined actions would be highly 
favourable in obesity-driven forms of diabetes, such as type 2 diabetes 
mellitus. Our studies confirmed inhibitory effects on food intake 
following individual administration of JMV-449, (D-Ala2)GIP or 
exendin-4 at a dose of 25 nmol/kg. Receptors for GIP, GLP-1 and neu-
rotensin are located within the paraventricular nuclei region of the 
hypothalamus, known to critical for energy regulation and metabolism 
[45–47], and likely mediates these effects. The excellent efficacy of 
exendin-4 alone at a dose of 25 nmol/kg precluded any conceivable 
additive appetite suppressive effects. However, with a reduced dose of 
exendin-4 there was good evidence for JMV-449 additive benefits on 
appetite reduction in mice. As such, it has been suggested that sub-
threshold doses of GLP-1 are required to induced appetite and weight 
loss synergy with neurotensin [3]. JMV-449 was also unable to enhance 
(D-Ala2)GIP mediated reductions in food intake, which may be peptide 
dose and model related. However, studies with GIP and xenin in rodents 
also suggest that unlike effects of glucose homeostasis and insulin 
secretion, these peptides lack additive positive actions on appetite 
control [21]. 
Although potential benefits of combined incretin and neurotensin 
signalling have been previously suggested [3,5], this is the first study to 
directly evaluate possible interplay between both incretin hormones and 
neurotensin. It is reassuring to note that JMV-449 evoked clear in vitro 
insulinotropic and in vivo glucose-lowering potentiating benefits in 
combination with GIP and GLP-1, suggesting no obvious threshold for 
these benefits. Appropriate dose adjustment within the in vivo series of 
experiments may have allowed for observation of further additive ben-
efits. With a view towards possible clinical application of our findings, 
the short sequence of JMV-449 is highly attractive, making it cheap and 
relatively easy to synthesise, as well as potentially allowing a non- 
injectable peptide drug administration [48]. In that regard, recent 
approval of oral delivery of the GLP-1 mimetic semaglutide [49], as well 
as confirmed oral bioavailability for DPP-4 inhibitor drugs [48], is 
encouraging. Moreover, advances in regulatory peptide drug design and 
development, leading to creation of functional unimolecular triple ag-
onists, represents another potential route to clinical realisation of the 
benefits of combined GIP, GLP-1 and neurotensin receptor signalling. 
In conclusion, these data establish that JMV-449 is an enzymatically 
stable and bioactive hexapeptide analogue of neurotensin, which pos-
sesses notable positive effects on pancreatic beta-cells. Furthermore, we 
clearly demonstrate the ability of JMV-449 to significantly potentiate 
the glucose homeostatic and insulin releasing actions of the incretin 
hormones, GIP and GLP-1. Further consideration is required to fully 
assess the clinical potential of upregulated neurotensin signalling in 
combination with approved incretin-based therapeutics. 
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